Friday, December 9, 2022, 11:30 AM – 1:30 PM CT (12:30 PM – 2:30 PM ET) – New Orleans, Louisiana

Addressing Current Questions and Controversies in the Management of Chronic Lymphocytic Leukemia — What Clinicians Want to Know (Part 1 of a 3-Part Series)

A CME Friday Satellite Symposium and Virtual Event Preceding the 64th ASH Annual Meeting

Location
Hyatt Regency New Orleans
601 Loyola Avenue
New Orleans, LA 70113
Hotel Phone: (504) 561-1234

Program Schedule — Central Time
11:00 AM – 11:30 AM — Registration and Lunch
11:30 AM – 1:30 PM — Educational Meeting

Meeting Room
Celestin Ballroom ABCD (Level 3)


This event will also be webcast live.
Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in New Orleans, preregistration is required as seating is limited.  
 
Faculty
Alexey V Danilov, MD, PhD
Professor, Department of Hematology and Transplantation
Co-Director, Toni Stephenson Lymphoma Center
City of Hope National Medical Center
Duarte, California

Matthew S Davids, MD, MMSc
Associate Professor of Medicine
Harvard Medical School
Director of Clinical Research
Division of Lymphoma
Dana-Farber Cancer Institute
Boston, Massachusetts

Professor Dr Arnon P Kater, MD, PhD
Dept of Hematology, Cancer Center
Amsterdam University Medical Centers
University of Amsterdam
Amsterdam, Netherlands


Lindsey Roeker, MD
Assistant Attending Physician
Memorial Sloan Kettering Cancer Center
New York, New York

Philip A Thompson, MB, BS
Associate Professor, Department of Leukemia
Division of Cancer Medicine
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Genentech, a member of the Roche Group, Lilly, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC.
Program Schedule — Central Time
11:00 AM – 11:30 AM — Registration and Lunch Buffet
11:30 AM – 1:30 PM — Educational Meeting

MODULE 1: Front-Line Treatment of Chronic Lymphocytic Leukemia (CLL) — Dr Danilov

  • Clinical, biologic and practical factors in the selection of first-line treatment for patients with CLL requiring active therapy
  • Long-term findings from Phase III studies assessing ibrutinib- and acalabrutinib-based therapy for treatment-naïve CLL
  • Available results from the Phase III SEQUOIA trial comparing zanubrutinib to bendamustine/rituximab as first-line therapy for previously untreated CLL
  • Outcomes observed with venetoclax-based up-front regimens for older/unfit and fit patients with treatment-naïve CLL
  • Importance, if any, of minimal residual disease (MRD) assessment in determining the duration of venetoclax-based up-front therapy; current and future role of MRD in clinical decision-making

MODULE 2: Novel Strategies Combining Bruton Tyrosine Kinase (BTK) and Bcl-2 Inhibitors for CLL — Prof Kater

  • Mechanistic rationale for combining BTK inhibitors, Bcl-2 inhibitors and/or anti-CD20 antibodies in the management of CLL
  • Efficacy outcomes from early-phase studies evaluating ibrutinib in combination with venetoclax for treatment-naïve and relapsed/refractory (R/R) CLL
  • Design, eligibility criteria and major efficacy and safety findings from the Phase III GLOW trial evaluating ibrutinib/venetoclax versus chlorambucil/obinutuzumab as first-line treatment for CLL
  • Outcomes reported in available data sets investigating acalabrutinib or zanubrutinib in combination with venetoclax, with or without an anti-CD20 antibody
  • Ongoing Phase III studies assessing novel doublet and triplet combinations for previously untreated and R/R disease

MODULE 3: Optimal Management of Adverse Events with BTK and Bcl-2 Inhibitors; Considerations for Special Patient Populations — Dr Davids

  • Importance of underlying comorbidities (eg, hypertension, chronic kidney or liver disease, atrial fibrillation) in clinical decision-making for patients with CLL
  • Incidence of side effects (eg, hemorrhage, atrial fibrillation, infections, cytopenias, hypertension, headache) with ibrutinib, acalabrutinib and zanubrutinib in published clinical trials
  • Implications for clinical decision-making of results from the Phase III ELEVATE-RR and ALPINE studies evaluating acalabrutinib and zanubrutinib, respectively, versus ibrutinib for previously treated disease
  • Pharmacokinetics, pharmacodynamics and safety of the maleate tablet formulation of acalabrutinib compared to standard capsules; recent FDA approval and current clinical role
  • Frequency of tumor lysis syndrome and other adverse events with venetoclax therapy in CLL clinical trials; recommended protocols for monitoring, prevention and management
  • Incidence and severity of clinically relevant toxicities encountered when combining BTK and Bcl-2 inhibitors with or without anti-CD20 antibodies

MODULE 4: Selection and Sequencing of Available Therapies for R/R Disease — Dr Thompson

  • Key factors in selecting therapy for patients who experience disease progression on first-line treatment
  • Long-term follow-up from Phase III trials evaluating BTK and Bcl-2 inhibitors for R/R CLL
  • Published data sets and ongoing studies exploring the role of rechallenge with an agent or class of agents received in a prior line of therapy
  • Available data with and clinical role of PI3 kinase inhibitors in CLL management
  • Emerging results with novel therapeutic strategies for patients with CLL and Richter’s transformation

MODULE 5: Promising Investigational Agents and Strategies — Dr Roeker

  • Pharmacologic similarities and differences between the investigational noncovalent BTK inhibitor pirtobrutinib and covalent BTK inhibitors; implications for efficacy and tolerability
  • Updated results among patients with R/R CLL in the BRUIN study of pirtobrutinib; potential clinical application
  • Biologic rationale for the investigation of CD19-directed chimeric antigen receptor (CAR) T-cell therapy for R/R CLL
  • Key findings from the lisocabtagene maraleucel (liso-cel) monotherapy and the liso-cel/ibrutinib cohorts of the TRANSCEND CLL 004 trial
  • Clinical and research implications of recent reports indicating long-term sustained remissions with functional persistence of CAR T cells after CAR T-cell therapy in patients with CLL
  • Other promising agents and strategies under investigation for CLL

Target Audience
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of chronic lymphocytic leukemia (CLL).

Learning Objectives
Upon completion of this activity, participants should be able to

  • Individualize the selection of systemic therapy for newly diagnosed CLL, considering new research findings, clinical presentation, biomarker profile, coexisting medical conditions and patient preferences.
  • Appraise available and emerging Phase III data documenting the comparative efficacy and tolerability of first- and second-generation Bruton tyrosine kinase (BTK) inhibitors, and consider the implications of these findings for clinical decision-making for patients with newly diagnosed or previously treated CLL.
  • Appreciate the scientific rationale for the investigation of combined BTK and Bcl-2 inhibition, and review recently presented data documenting the safety and efficacy of this strategy for newly diagnosed CLL.
  • Analyze how patient age, performance status, prior therapeutic exposure and other biologic and disease-related factors affect the selection and sequencing of therapy for relapsed/refractory (R/R) CLL.
  • Discuss available clinical research demonstrating the efficacy and safety of noncovalent BTK inhibitors in patients with CLL, and use this information to evaluate the potential role of these agents in the treatment of R/R disease.
  • Implement a plan of care to recognize and manage side effects and toxicities associated with recently approved and emerging systemic therapies for CLL.
  • Recall available data with novel agents and combination strategies currently under investigation for CLL, and refer eligible patients for clinical trial participation.

CME Credit Form
A CME credit link will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Danilov — Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Incyte Corporation, Lilly, MorphoSys, Nurix Therapeutics Inc, Oncovalent Therapeutics, Pharmacyclics LLC, an AbbVie Company, TG Therapeutics Inc; Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Cyclacel Pharmaceuticals Inc, MEI Pharma Inc, Nurix Therapeutics Inc, Takeda Pharmaceuticals USA Inc. Dr Davids — Advisory Committee: AbbVie Inc, Adaptive Biotechnologies Corporation, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Janssen Biotech Inc, Lilly, Merck, Takeda Pharmaceuticals USA Inc, TG Therapeutics Inc; Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, Ascentage Pharma, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Janssen Biotech Inc, Lilly, Merck, Ono Pharmaceutical Co Ltd, Takeda Pharmaceuticals USA Inc, TG Therapeutics Inc, Verastem Inc; Contracted Research: AbbVie Inc, Ascentage Pharma, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Novartis, TG Therapeutics Inc, Verastem Inc. Prof Kater — Advisory Committee and Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Janssen Biotech Inc, LAVA Therapeutics NV, Roche Laboratories Inc; Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Janssen Biotech Inc, LAVA Therapeutics NV, Link Immunotherapeutics Inc, Roche Laboratories Inc; Speakers Bureau: AbbVie Inc. Dr Roeker — Consulting Agreements: AbbVie Inc, Ascentage Pharma, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Janssen Biotech Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, TG Therapeutics Inc; Contracted Research: Aptos Biosciences, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Pfizer Inc, Sound Biologics; Stock Options/Ownership — Public Ineligible Company: Abbott Laboratories; Speaking Engagements: Curio Bioscience, DAVA Oncology; Travel Support: Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company. Dr Thompson — Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Genentech, a member of the Roche Group, Janssen Biotech Inc, Lilly; Contracted Research: AbbVie Inc, Adaptive Biotechnologies Corporation, AstraZeneca Pharmaceuticals LP, Lilly.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Genentech, a member of the Roche Group, Lilly, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC.

Location
Hyatt Regency New Orleans
601 Loyola Avenue
New Orleans, LA 70113
Phone: (504) 561-1234

Meeting Room
Celestin Ballroom ABCD (Level 3)

Directions
Hyatt Regency New Orleans is conveniently located 6 minutes (1.1 miles) from the Ernest N Morial Convention Center, where the 64th ASH Annual Meeting is taking place. ASH will be providing complimentary shuttle service between the convention center and participating conference hotels. Shuttle schedule information will be made available on the ASH conference website and also posted in the lobby of participating hotels.

This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of chronic lymphocytic leukemia.

​ ​ ​
IN-PERSON registration for clinicians in practice/healthcare professionals
Thank you for your interest in our CME program. At this time online preregistration is closed for this in-person event. SEATS ARE STILL AVAILABLE FOR THE SESSION. Our onsite registration desk will be open at 11:00 AM CT on Friday, December 9th. If you are interested in attending, please visit our registration desk outside the Celestin Ballroom ABCD (Level 3) of the Hyatt Regency New Orleans hotel (601 Loyola Avenue).

Hyatt Regency New Orleans is conveniently located 6 minutes (1.1 miles) from the Ernest N Morial Convention Center, where the 64th ASH Annual Meeting is taking place. ASH will be providing complimentary shuttle service between the convention center and participating conference hotels. Shuttle schedule information will be made available on the ASH conference website and also posted in the lobby of participating hotels.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.

NOTICE:
Registration for this event is independent of registration for the ASH Annual Meeting.

LIVE WEBCAST registration for all professionals

Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

REGISTRATION FOR WEBCAST »

Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.